注射用苯磺酸瑞马唑仑 | China Drugs ListRemimazolam besylate for injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 麻醉与疼痛Anesthesia & pain
- 公开来源记录的适应症
- 作为镇静药物用于:（1）非气管插管的手术或操作中的镇静和麻醉;（2）全身麻醉的诱导和维持;（3）重症监护期间机械通气时的镇静。1. Sedation and anesthesia for surgery or procedures without tracheal intubation. 2. Induction and maintenance of general anesthesia. 3. Sedation during mechanical ventilation in intensive care.
- 适应症来源与口径
- 来源日期： 2025. 新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2025. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限：1.非气管插管手术/操作中的镇静和麻醉；2.全身麻醉的诱导和维持。 || 限：1.非气管插管的手术/操作中的镇静和麻醉；2.全身麻醉诱导与维持。Limited to: 1. Sedation and anesthesia for surgery or procedures without tracheal intubation. 2. Induction and maintenance of general anesthesia.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.